Zydus Lifesciences informs about press release

30 Aug 2022 Evaluate
Zydus Lifesciences has informed about Press Release dated August 30, 2022 titled 'Zydus announces Phase IV DREAM-CKD trial to generate Real World Evidence of Desidustat in patients with chronic kidney disease induced anemia'.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

886.30 -19.70 (-2.17%)
16-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.55
Dr. Reddys Lab 1275.05
Cipla 1298.80
Zydus Lifesciences 886.30
Lupin 2290.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×